XML 43 R28.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Quarterly Financial Data | 12 Months Ended
--- | ---
Dec. 31, 2015
Quarterly Financial Data |
Quarterly Financial Data | 20. Quarterly Financial Data (Unaudited)
|  | 2015 Quarters |
|  | First |  | Second |  | Third |  | Fourth |
Net revenues |  |  |  |  |  |  |  |  |  |  |  |  |
Finished pharmaceutical products |  | $ | 50,872 |  | $ | 50,075 |  | $ | 57,902 |  | $ | 66,092 |
API |  |  | 6,014 |  |  | 3,778 |  |  | 5,966 |  |  | 10,820 |
Total net revenues |  | $ | 56,886 |  | $ | 53,853 |  | $ | 63,868 |  | $ | 76,912 |
Gross profit |  |  |  |  |  |  |  |  |  |  |  |  |
Finished pharmaceutical products |  | $ | 12,853 |  | $ | 12,634 |  | $ | 19,302 |  | $ | 29,357 |
API |  |  | 427 |  |  | 684 |  |  | (1,724) |  |  | 3,814 |
Total gross profit |  | $ | 13,280 |  | $ | 13,318 |  | $ | 17,578 |  | $ | 33,171 |
Net income (loss) |  | $ | (665) |  | $ | (6,647) |  | $ | (3,008) |  | $ | 7,533 |
Weighted-average shares used to compute net income (loss) per share |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  | 44,601 |  |  | 44,849 |  |  | 45,310 |  |  | 45,085 |
Diluted |  |  | 44,601 |  |  | 44,849 |  |  | 45,310 |  |  | 46,709 |
Net income (loss) per share |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | (0.01) |  | $ | (0.15) |  | $ | (0.07) |  | $ | 0.17 |
Diluted |  | $ | (0.01) |  | $ | (0.15) |  | $ | (0.07) |  | $ | 0.16 |
|  | 2014 Quarters |
|  | First |  | Second |  | Third |  | Fourth |
Net revenue |  |  |  |  |  |  |  |  |  |  |  |  |
Finished pharmaceutical products |  | $ | 45,870 |  | $ | 48,901 |  | $ | 53,729 |  | $ | 49,980 |
API |  |  | — |  |  | 102 |  |  | 5,982 |  |  | 5,897 |
Total net revenues |  | $ | 45,870 |  | $ | 49,003 |  | $ | 59,711 |  | $ | 55,877 |
Gross profit |  |  |  |  |  |  |  |  |  |  |  |  |
Finished pharmaceutical products |  | $ | 12,509 |  | $ | 14,961 |  | $ | 12,122 |  | $ | 13,132 |
API |  |  | — |  |  | 35 |  |  | (331) |  |  | (1,172) |
Total gross profit |  | $ | 12,509 |  | $ | 14,996 |  | $ | 11,791 |  | $ | 11,960 |
Net loss |  | $ | (1,619) |  | $ | (1,180) |  | $ | (5,379) |  | $ | (2,521) |
Weighted-average shares used to compute net loss per share |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  | 38,769 |  |  | 39,767 |  |  | 44,644 |  |  | 44,648 |
Diluted |  |  | 38,769 |  |  | 39,767 |  |  | 44,644 |  |  | 44,648 |
Net loss per share |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | (0.04) |  | $ | (0.03) |  | $ | (0.12) |  | $ | (0.06) |
Diluted |  | $ | (0.04) |  | $ | (0.03) |  | $ | (0.12) |  | $ | (0.06) |
Net income (loss) per share amounts for the fiscal quarters have been calculated independently and may not in the aggregate equal the amount for the full year. During the fourth quarter of 2015, the Company identified an immaterial error in each of its previously reported quarters of 2015, primarily pertaining to the result of not recognizing non-operating expense for certain foreign currency trans actions. The Company corrected the immaterial error in the fourth quarter of 2015, resulting in a decrease to net income of $1.1 million. Based on management's evaluation of the materiality of the error from a qualitative and quantitative perspective as required by authoritative guidance, the Company concluded that correcting the error had no material impact on any of the Company's previously issued interim financial statements and had no effect on the trend of financial results.

X
- References No definition available. + Details
Name: | us-gaap_QuarterlyFinancialInformationDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 45 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e765-108305 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a)-(j) -URI http://asc.fasb.org/extlink&oid=51825399&loc=d3e1280-108306 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 45 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e725-108305 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 6 -Section G -Subsection 1 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K (SK) -Number 229 -Section 302 -Paragraph a + Details
Name: | us-gaap_QuarterlyFinancialInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration